Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-04-20

Clinical Trial Update: Trial of RAD001 in Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of RAD001 (everolimus) in triple-negative metastatic breast cancer was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RAD001 (everolimus)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-04-20